In this project, Neuropsychological data will be obtained at baseline from controls and non-demented subjects with cognitive impairments who will be recruited through the Clinical Core and followed over time. The overall goal of the Neuropsychological project is to determine whether neuropsychological data can be used to predict which non-demented individuals with cognitive problems will develop progressive cognitive data, which will progress to the pint where they meet criteria for AD, and which will remain stable. By adding two neuropsychological tests to the annual review in which the subjects participate, we also propose to determine whether such testing can serve as a surrogate for a detailed clinical interview by a skilled clinician. In addition, we will seek to determine the relationship between neuropsychological measures and other information obtained on the same individuals by the cores and the projects, including clinical data, genotype status, volumeric MRI, cerebral perfusion, and fMRI signal change. An implicit assumption underlying the goals of the project is that, by examining the performance of non-demented individuals with a range of cognitive difficulty, and relating performance to a variety of measures that reflect the in vivo status of the brain, as well as other relevant clinical and genetic data, it will be possible to determine the evolution of brain changes that occur during prodromal AD, and the neuropsychological measures that are best suited to identifying these changes.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
2P01AG004953-19
Application #
6548802
Study Section
Special Emphasis Panel (ZAG1-FAS-3 (M1))
Project Start
1984-08-01
Project End
2007-07-31
Budget Start
Budget End
Support Year
19
Fiscal Year
2002
Total Cost
$143,985
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Tosto, Giuseppe; Monsell, Sarah E; Hawes, Stephen E et al. (2016) Progression of Extrapyramidal Signs in Alzheimer's Disease: Clinical and Neuropathological Correlates. J Alzheimers Dis 49:1085-93
Herold, C; Hooli, B V; Mullin, K et al. (2016) Family-based association analyses of imputed genotypes reveal genome-wide significant association of Alzheimer's disease with OSBPL6, PTPRG, and PDCL3. Mol Psychiatry 21:1608-1612
D'Avanzo, Carla; Aronson, Jenna; Kim, Young Hye et al. (2015) Alzheimer's in 3D culture: challenges and perspectives. Bioessays 37:1139-48
Weissmiller, April M; Natera-Naranjo, Orlangie; Reyna, Sol M et al. (2015) A ?-secretase inhibitor, but not a ?-secretase modulator, induced defects in BDNF axonal trafficking and signaling: evidence for a role for APP. PLoS One 10:e0118379
Liu, Qing; Waltz, Shannon; Woodruff, Grace et al. (2014) Effect of potent ?-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers. JAMA Neurol 71:1481-9
Liang, Steven H; Yokell, Daniel L; Jackson, Raul N et al. (2014) Microfluidic continuous-flow radiosynthesis of [(18)F]FPEB suitable for human PET imaging. Medchemcomm 5:432-435
Choi, Se Hoon; Kim, Young Hye; Hebisch, Matthias et al. (2014) A three-dimensional human neural cell culture model of Alzheimer's disease. Nature 515:274-8
Fung, Wai Lun Alan; Naylor, Melissa G; Bennett, David A et al. (2013) Principal components methods for narrow-sense heritability in the analysis of multidimensional longitudinal cognitive phenotypes. Am J Med Genet B Neuropsychiatr Genet 162B:770-8
Macklin, Eric A; Blacker, Deborah; Hyman, Bradley T et al. (2013) Improved design of prodromal Alzheimer's disease trials through cohort enrichment and surrogate endpoints. J Alzheimers Dis 36:475-86
Johnson, Keith A; Sperling, Reisa A; Gidicsin, Christopher M et al. (2013) Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 9:S72-83

Showing the most recent 10 out of 104 publications